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CaMKII inhibition rectifies arrhythmic phenotype
in a patient-specific model of catecholaminergic
polymorphic ventricular tachycardia
E Di Pasquale1,9,10, F Lodola2,9, M Miragoli3,4, M Denegri2, JE Avelino-Cruz2,11, M Buonocore5, H Nakahama3, P Portararo6, R Bloise2,
C Napolitano2,7, G Condorelli*,4 and SG Priori*,2,7,8
Induced pluripotent stem cells (iPSC) offer a unique opportunity for developmental studies, disease modeling and regenerative
medicine approaches in humans. The aim of our study was to create an in vitro ‘patient-specific cell-based system’ that could
facilitate the screening of new therapeutic molecules for the treatment of catecholaminergic polymorphic ventricular tachycardia
(CPVT), an inherited form of fatal arrhythmia. Here, we report the development of a cardiac model of CPVT through the generation
of iPSC from a CPVT patient carrying a heterozygous mutation in the cardiac ryanodine receptor gene (RyR2) and their
subsequent differentiation into cardiomyocytes (CMs). Whole-cell patch-clamp and intracellular electrical recordings of
spontaneously beating cells revealed the presence of delayed afterdepolarizations (DADs) in CPVT-CMs, both in resting
conditions and after b-adrenergic stimulation, resembling the cardiac phenotype of the patients. Furthermore, treatment with
KN-93 (2-[N-(2-hydroxyethyl)]-N-(4methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-methylbenzylamine), an antiarrhythmic
drug that inhibits Ca2þ /calmodulin-dependent serine–threonine protein kinase II (CaMKII), drastically reduced the presence of
DADs in CVPT-CMs, rescuing the arrhythmic phenotype induced by catecholaminergic stress. In addition, intracellular calcium
transient measurements on 3D beating clusters by fast resolution optical mapping showed that CPVT clusters developed
multiple calcium transients, whereas in the wild-type clusters, only single initiations were detected. Such instability is
aggravated in the presence of isoproterenol and is attenuated by KN-93. As seen in our RyR2 knock-in CPVT mice, the
antiarrhythmic effect of KN-93 is confirmed in these human iPSC-derived cardiac cells, supporting the role of this in vitro system
for drug screening and optimization of clinical treatment strategies.
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Induced pluripotent stem cell (iPSC) technology has been
proposed as a valuable approach for studying the
pathophysiology of human diseases in vitro. iPSCs are
generated by the reprogramming of somatic cells through
the expression of ectopic transcription factors, and
have been shown to be able to differentiate into all cell
types of the body, including functional cardiomyocytes
(CMs).1–3
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The usefulness of reprogrammed cells in modelling
diseases in vitro has recently been tested for several human
congenital cardiovascular diseases: iPSCs have been used
for the investigation of monogenic disorders (i.e. long QT
(prolongation of Q–T interval combined with torsades de
pointes and manifests as several different forms) syndromes,
Brugada syndrome/cardiac conduction disease, catechola-
minergic polymorphic ventricular tachycardia and other forms
of congenital arrhythmias) and disorders in which cardiac
defects are part of a multiorgan phenotype (i.e. Leopard and
Timothy syndromes). These reports confirmed that patient-
specific iPSCs are able to give rise to differentiated CMs that
possess the main functional and morphological aberration
typical of the disease in vivo.1,4–13 Furthermore, the impor-
tance of iPSC in drug discovery applications is useful to
identify novel therapeutic molecules and devise patient-
specific therapies.5,6,8
In our study, we focused on catecholaminergic polymorphic
ventricular tachycardia (CPVT), a highly lethal inherited
arrhythmogenic disease that may cause syncope and sudden
death early in life owing to adrenergically mediated bidirec-
tional ventricular tachycardia. Two genetic forms of the
disease have been described: one transmitted as an auto-
somal dominant trait, caused by mutations in the gene
encoding the ryanodine receptor type 2 (RyR2), and another
very rare form due to recessive mutations in the cardiac-
specific isoform of the calsequestrin gene, CASQ2 (calse-
questrin 2).14,15 Both genes are involved in regulating Ca2þ
handling within the CM and thus are key in determining
excitation–contraction coupling.16,17
Although the mortality rate associated with the disease is
extremely high (30–35% by the age of 35 years), therapies are
limited. Treatment with b-adrenergic blockers are usually
effective in preventing recurrences of arrhythmias in the
majority of patients, but approximately 30% of patients still
experience at least one episode of life-threatening adrenergi-
cally induced arrhythmia (leading to syncope or cardiac arrest)
despite therapy and will need implantable cardioverter
defibrillators.18,19
Therefore, development of model systems facilitating
screening of new therapeutic molecules for the treatment of
CPVT is highly advisable.
Among the putative players in determining the CPVT
phenotype, Ca2þ /calmodulin-dependent serine–threonine
protein kinase II (CaMKII) has been recently implicated in
arrhythmic events elicited by b-adrenergic activation, and we
recently demonstrated that its inhibition is able to prevent
ventricular arrhythmogenesis in a mouse model of CPVT.20–22
With these considerations in mind, our intent was to create a
patient-specific cell-based system that could be used as an
in vitro model to facilitate the screening of new therapeutic
molecules for the treatment of CPVT. For this purpose, we
generated an iPSC-based cardiac model from a patient
carrying a heterozygous mutation in the gene encoding
RyR2 and with phenotypic manifestations of the disease.
In a first instance, we verified that the disease phenotype
was recapitulated in the CMs derived from these iPSC.
Subsequently, we inhibited the Ca2þ -CaMKII pathway, which
affects calcium handling, to test whether we could rescue the
disease phenotype in human cardiac cells to confirm the
clinical relevance of the observation made in myocytes
derived from knock-in mice carriers of a heterozygous defect
in RyR2 and presenting the clinical phenotype of CPVT.
Our results support the view that iPSC technology is likely to
have clinical applicability to predict response to therapy in
individual patients.
Results
Clinical history. In June 2006, the team of our outpatient
clinic for inherited arrhythmia at the Maugeri Foundation was
contacted for the assessment of a family with a history of
juvenile sudden cardiac death. The proband (Figure 1A,
subject II-2), a 42-year-old female reported that two of her
children died suddenly before age 10 years (Figure 1A,
subjects III-1 and III-2) both in a condition of adrenergic
stress. III-1 died at the age of 8 years while riding on a
carousel and III-2 died suddenly at the age of 9 years running
in a school competition. The mother also reported that III-1
experienced a syncopal spell during physical activity a few
months before dying. At that time, the boy was taken to the
emergency room, but resting electrocardiogram (ECG) and
echocardiogram were unremarkable and he was discharged.
The other child of the proband, that is, III-2, died at the age of
9 years with no previous symptoms. At first clinical
evaluation, the mother (II-2) reported two previous episodes
of loss of consciousness during physical activity (at the age
of 41 and 42 years) and reported that in a previous exercise
stress test there was documentation of isolated premature
ventricular contractions and a ventricular couplet that
resulted in the interruption of the test. We recorded her
resting ECG (Figure 1B) and echocardiogram, which were
unremarkable. However, maximal exercise stress test
documented the onset of sustained bidirectional ventricular
tachycardia (Figure 1B). CPVT diagnosis was established
and b-blocker therapy was administered. A second exercise
stress test after 5 days of therapy with nadolol (2 mg/kg)
showed suppression of arrhythmias after maximally tolerated
effort. The patient has remained asymptomatic, with no
evidence of arrhythmias as of September 2012. Sequencing
of the entire open reading frame of the RyR2 gene identified
the c.6933 G4C nucleotide transversion in exon 46, leading
to the p.Glu2311Asp missense mutation. Unfortunately, no
post-mortem samples were available for the deceased
children. Genetic testing also identified the same mutation
in the asymptomatic two-year-old daughter (III-3), who was
promptly treated with oral nadolol (2 mg/kg). Holter monitor-
ing off therapy showed rare supraventricular and ventricular
ectopic beats that disappeared after therapy.
Generation of patient-specific CPVT-iPSC and their
characterization. CPVT-iPSCs were generated from
primary fibroblasts isolated from a skin biopsy of the proband
through lentiviral transduction with OCT4 (octamer-binding
transcription factor 4), SOX2 (SRY (sex determining
region Y)-box 2), NANOG (homeobox transcription factor)
and LIN-28 (zinc-finger CCHC domain-containing protein 1).
Before induction, isolated primary skin cells exhibited the
morphology (Figure 1Ca) and antigenic expression pattern
of human fibroblasts (Supplementary Figure 1). Several
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patient-specific iPSC clones were generated from them and
clones have been selected by their morphological similarity to
human ES cells and expanded (Figure 1C). Two iPSC lines
were chosen, further characterized and used for differentiat-
ing into patient-specific CMs. As a control, iPSCs generated
from a healthy subject were used (Supplementary Figure 2).23
As a first step, we verified that iPSCs generated were
genetically matched to the donor and that those derived from
the patient carried the heterozygous p.Glu2311Asp RyR2
gene mutation (RyR2-Heþ / ), by direct sequencing
(Figure 1D). No chromosomal abnormalities were detected
by karyotype analysis (Figure 1E).
To establish that reprogramming had occurred correctly
and that the selected iPSC clones were pluripotent, we tested
whether these lines expressed pluripotency markers by
verifying alkaline phosphatase activity ((Figure 1Cc and
Supplementary Figure 2C), the expression of ‘stemness’-
associated antigens (tumor rejection antigen 1–60 (TRA1–60)
and stage-specific embryonic antigen 4 (SSEA4)) and
transcription factors (OCT4, REX1 (RNA exonuclease 1
homolog), DNA (cytosine-5)-methyltransferase 3b (DNMT3B))
with different approaches, that is, immunofluorescence
staining (Figure 1C and Supplementary Figure 2), real-time
polymerase chain reaction (PCR) (Supplementary Figure 3A)
and fluorescence-activated cell sorting (FACS) analysis
(Supplementary Figures 3B and C).
Pluripotent cells are by definition capable of differentiating
into all cell types of the body. Accordingly, iPSCs are able to
spontaneously differentiate into cell types derived from each
of the three germ layers when cultured in suspension to form
EBs. To test the developmental properties of the selected
iPSC lines, we induced differentiation with the EB aggregation
method: immunohistochemical analysis (Figure 2A and
Supplementary Figure 4) and semiquantitative real-time
PCR (Figure 2B) revealed that the EBs contained cells
expressing markers of the ectodermal (NCAM1 (neural cell
adhesion molecule 1), KRT14 (epidermal keratin 14),
bIII-tubulin, nestin), mesodermal (a-smooth muscle actin,
desmin,PECAM1 (platelet/endothelial cell adhesion molecule
1) and cardiac genes) and endodermal (GATA6, SOX17
(SRY-box containing gene 17) and a-fetoprotein) lineages.
Moreover, control- and CPVT-iPSC injected into immuno-
compromised mice had the ability to form teratomas containing
derivatives of all the three germ layers. This provided more
stringent evidence of the pluripotency of these lines
(Figure 2C).
Altogether, these data indicate that we have reprogrammed
fibroblasts from a patient with CPVT into iPSC.
Figure 1 Generation of iPSC from a CPVT patient skin biopsy. (A) Pedigree of the RyR2-Heþ / CPVT kindred modeled in this study. Proband (II-2) is indicated by an
arrow. Filled symbols indicate clinically and genetically affected subjects. Half-black symbols indicate genetically affected individuals, and upper half-black symbols indicate
sudden cardiac death cases. Square¼male; circle¼ female. (B) Example of bidirectional ventricular tachycardia recorded off-therapy in the proband (paper speed 25mm/s).
(C) Representative images of dermal fibroblasts derived from the CPVT patient (a) and of an iPSC colony derived from the patient’s fibroblasts (b) showing alkaline
phosphatase activity (c) and positivity for the pluripotency markers OCT4 (d), TRA1-60 (e) and SSEA4 (f). Scale bars¼ 100mm. (D) Sequencing analysis confirming that the
CPVT-iPSC line (He) carried the specific G-to-C mutation on one allele of the RyR2 gene, whereas control-iPSC (WT) did not show any genetic alteration. (E) iPSC lines
maintained a normal karyotype after expansion
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Cardiac differentiation. As a next step, we induced iPSC to
differentiate toward the cardiac lineage. Control- and CPVT-
iPSC lines developed spontaneously contracting areas
(Supplementary Movie 1) expressing cardiac-specific chan-
nel and structural genes (Figures 3a and b). Importantly,
western blot analysis revealed specific expression of RyR2 in
iPSC-derived beating explants, either wild-type (WT) or
CPVT, at comparable levels (Figures 3b and c). Immunos-
taining analysis confirmed the presence and the distribution
of RyR2 in cells isolated from the contracting areas
(Figure 3d and Supplementary Movie 2).6,24
Characterization of iPSC-derived CMs reveals differentiation
of heterogeneous populations of cardiac cells. As a
first step in the characterization process, we evaluated
the electrical activity of control- and CPVT-iPSC-derived
CMs.
The analysis of the main electrical features evidenced that
the mean amplitude of the AP was around 20 mV higher in
CPVT-CMs than in control-CMs, whereas the action potential
duration at 30, 50 and 90% of repolarization (APD30, APD50
and APD90 respectively), the maximum diastolic potential
(MDP) as well as the maximal rate of depolarization and
Figure 2 Developmental properties of CPVT-iPSC confirm their pluripotency. (A) Phase-contrast (Phc) image of EBs from CPVT-iPSC at day 6 after formation.
Immunostaining of differentiated CPVT-iPSC showing EBs containing cells representative of each of the three embryonic germ layers: endoderm (a-fetoprotein for intestinal
cells), ectoderm (bIII tubulin for neuronal cells) and mesoderm (a-smooth muscle actin for skeletal muscle, a SMA); nuclei were stained with DAPI. Scale bars¼ 100mm;
(B) semiquantitative real-time PCR of differentiated control- (WT) and CPVT-iPSC at days 30 and 50 of differentiation, showing upregulation of expression of markers of the
three germ layers: positivity for NCAM1, bIII-tubulin and KRT14was indicative of ectodermal cells (neurons or epidermis); the presence of DESMIN and PECAM1 indicated the
presence of mesodermal cells; and the transcription factors GATA6 and SOX17 were indicative of endodermal differentiation. Data are presented relative to undifferentiated
iPSC and were normalized to HGPRT (hypoxanthine–guanine phosphoribosyltransferase) and GAPDH (glyceraldehyde 3-phosphate dehydrogenase). Values are
mean±S.D. *Po0.05; (C) teratoma formation assay: hematoxylin–eosin staining (a–c) and immunohistochemistry (d–f) of teratomas formed from CPVT-iPSC
(representative images from one cell line), showing differentiation of cells injected in vivo into various tissues derived from all the three germ layers: retinal epithelium and
neural rosettes derive from ectoderm (d); cartilage and muscle (positivity for a-actinin) are mesodermal tissues (e); whereas the presence of respiratory and intestinal
(cytokeratin-20 (CK-20) positive) epithelium is indicative of endodermal differentiation (f)
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maximal upstroke velocity were similar in both groups
(Figure 3f).
Importantly, during the diastolic depolarization phase,
CPVT-CMs had delayed afterdepolarizations (DADs), a
prominent feature of mature CMs with a CPVT phenotype
(Figure 3e).
Furthermore, as already reported in the literature, a more
detailed electrical characterization of both control and CPVT
cells lines showed that the differentiation process of these
cells reflected the heterogeneity seen in the heart.3,11,24
In particular, analyzing the cells for a variety of parameters,
including the maximal upstroke velocity (dV/dtmax), APD50,
APD90 and AP amplitude, it was possible to cluster two distinct
populations of iPSC-derived CMs (iPSC-CMs) in both the
cells line: nodal cells (i.e. cells from the AV node), which were
distinguishable because of their pronounced phase 4
depolarization preceding the onset of the AP, and working
myocardial cells (i.e. atrial and ventricular chamber), which
presented the typical plateau phase and, therefore, had the
longest AP duration (Supplementary Figure 5).11,24
b-Adrenergic stimulation-induced DADs and triggered
activity in CPVT-CMs. To assess the effect of b-adrenergic
stimulation on CPVT-CMs, we recorded evoked (Figure 4a)
and spontaneous (Figure 4b) APs before and after super-
fusion with the b-adrenergic agonist isoproterenol (Iso)
(1 mM). CPVT-CMs presenting spontaneous AP developed
DADs already at basal conditions in 43% of the cases (15 out
of 35), and b-adrenergic stimulation significantly increased
the frequency of this phenomenon, a hallmark of mature CMs
from CPVT patients (75% of the cases, 12 out of 16;
Figure 4b, indicated with black arrows). Furthermore, CPVT-
CMs also developed DADs and triggered activity (TA) when
paced at 0.5 Hz (12%, 2 out of 16, Figure 4a), confirming the
Figure 3 iPSC can differentiate into functional CMs. (a) Reverse transcription-polymerase chain reaction (RT-PCR) for the expression of cardiac-specific genes in control-
(WT) and CPVT-iPSC-derived beating explants (beating EBs); undifferentiated iPSCs and FHs were used as negative and positive controls, respectively. HGPRT:
housekeeping gene; CACNA1C: calcium channel, voltage-dependent, a1A subunit; SCN5A: sodium channel, voltage-gated, type V, alpha subunit; KCNQ1: potassium,
voltage-gated channel, KQT-like subfamily, member 1;MHCa: myosin heavy-chain a;MHC b: myosin heavy chain b. (b) Western blot of WT- and CPVT-IPSC-derived beating
explants for RyR2. b-Actin was used as the loading control, and human FH was used as a positive control. (c) RyR2 expression quantification in WT- and CPVT- beating
explants, calculated as densitometry RyR2/b-actin ratio (the diagram represents the mean of four independent experiments). (d) Immunostaining of CPVT-iPSC-derived CMs
for a-actinin and RyR2. Nuclei stained in DAPI. Scale bar¼ 20mm. (e) Representative traces of spontaneous APs recorded in iPSC harvested from the healthy donor
(WT-iPSC-CMs, left) and the patient carrying the CPVT mutation (CPVT-iPSC-CMs, right). A DAD is indicated by the arrow. (f) The main AP features measured in both
iPSC-derived lines: overshoot, amplitude, MDP, maximal upstroke velocity, maximal repolarization velocity and AP duration at 30%, 50% or 90% of repolarization (respectively
APD30, APD50 and APD90). WT-iPSC-CMs, n¼ 26; CPVT-iPSC-CMs, n¼ 35. Values are mean±MSE
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ability of our model system to recapitulate the disease
phenotype in vitro.
KN-93 exerts an antiarrhythmic effect on CVPT-CMs. To
prove the feasibility of our iPSC-based model for drug
discovery and for testing the efficacy of novel therapeutic
molecules, we cotreated CPVT-CMs with KN-93 (2-[N-
(2-hydroxyethyl)]-N-(4methoxybenzenesulfonyl)]amino-N-(4-
chlorocinnamyl)-N-methylbenzylamine), a CaMKII inhibitor.
We recently reported that KN-93 is the most powerful
antiarrhythmic agent that prevents ventricular arrhythmias
in our RyR2R4496Cþ / knock-in mouse model of CPVT.
KN-93 was also capable of abolishing DADs and TA in
isolated CMs in vitro.21
Consistent with the findings obtained in CMs derived from
the CPVT knock-in mice, 1mM KN-93 blunted Iso-induced
DADs in iPSC-derived CPVT-CMs (n¼ 7, versus Iso,
Po0.05; Figure 4), whereas the inactive stereoisomer
KN-92 (2-[N-(4-methoxybenzenesulfonyl)]amino-N-(4-chloro-
cinnamyl)-N-methylbenzylamine, phosphate) (1 mM) has no
effect on these arrhythmic events (n¼ 5,Po0.05 versusKN-93).
Importantly, the AP morphology of control-iPSC-derived CMs
did not undergo any noticeable changes when exposed to
KN-93 (data not shown).
We repeated the same protocol using 3D beating clusters of
control- and CPVT-iPSC-derived CMs, optically assessing
intracellular calcium transients after loading with Fluo-4 (2-{[3-
(2-{2-[bis(carboxymethyl)amino]-5-(2,7-difluoro-6-hydroxy-
3-oxo-3H-xanthen-9-yl)phenoxy}ethoxy)-4-methylphenyl]
(carboxymethyl)amino}acetic acid). We found that in CPVT-CMs,
calcium transients initiated from multiple locations within each
beating cluster (n¼ 8; Figure 5b and Supplementary Movie 3)
and that the impulses collided during the propagation,
generating a non-homogeneous spreading of calcium tran-
sients. This condition was exacerbated by b-adrenergic
stimulation during superfusion of the preparation with Iso. In
this setting, the number of areas generating spontaneous
calcium transients was increased. When we superfused the
CPVT multicellular preparations, we observed that KN-93
stabilized calcium activation, reverting to the typical pattern
observed in normal tissue, characterized by a single initiation
site located on the periphery of the preparation where the
Figure 4 KN-93 exerts an antiarrhythmic effect on CPVT-iPSC-derived CMs. Representative traces of evoked (a) and spontaneous (b) APs from CPVT-iPSC in the
presence of a b-adrenergic stimulus (1 mM Iso). DADs are indicated by arrows. (c) Coperfusion with 1 mM KN-93, a CaMKII inhibitor, prevented this arrhythmogenic effect in
CPVT-iPSC-derived CMs (n¼ 7, Po0.05)
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source-to-sink load was favorable.25 As expected, control
beating clusters had a single region of calcium impulse
initiation under basal conditions and during Iso administration
(n¼ 6; Figure 5a). Moreover, in 75% of the experiments (six
out of eight), the upstroke of the Ca2þ transient in CPVT
clusters in the presence of Iso had a double slope before
reaching the peak (Figure 5b, middle panel). To note, KN-93
recovered this abnormal feature of the calcium upstroke. This
may explain why the rate of intracellular calcium increase
(dCa2þ /dt) after the addition of the CaMKII inhibitor slightly
decreased (Figure 6c, versus Iso, not statistically significant),
whereas the time to reach the peak was significantly reduced
(Po0.05, versus Iso; Figure 6b).
Discussion
A little more than a decade ago, mutations in the cardiac
ryanodine receptor gene (RyR2) were first associated with
CPVT, a life-threatening inherited arrhythmogenic disorder.15
Since then, much has been learnt about the pathogenesis of
this disease: experimental findings from lipid bilayers as well
as knock-in and knockout mouse models suggested that the
mechanism underlying the onset of arrhythmia in CPVT
patients strictly relies on defective Ca2þ mobilization within
the CM during excitation–contraction coupling. Diastolic Ca2þ
leak from the sarcoplasmic reticulum is believed to be the
major player for the development of DADs, typical markers of
electrical instability in CPVT-CMs. DADs are elicited by
intracellular calcium load, which activates the membrane
Naþ /Ca2þ exchanger in an electrogenic mode derived by the
exchange of one Ca2þ for three Naþ , leading to diastolic
membrane depolarizations that may reach the activation
threshold for inward sodium current and generate triggered
beats that may eventually lead to sustained arrhythmias.26,27
The development of novel therapeutic approaches has
been limited and the use of implantable defibrillators remains
the therapy of choice for patients unresponsive to the
therapeutic options. Furthermore, the only disease models
of CPVT are the knock-in mice that have been used by us, and
others, to test new drugs.21 However, the results obtained in
myocytes from mice leaves investigators with the uncertainty
of whether the antiarrhythmic effect seen is replicated in
humans.
Clearly, the inability to study the disease and test new
treatments in human diseased CMs represents a major
limitation. Furthermore, accessibility to human cardiac tissue
is limited to heart surgery or to post mortems.
The advent of human iPSC technology may solve these
issues and revolutionize the investigation of pathological
molecular events driving human diseases: these cells offer an
Figure 5 Calcium transient detection in iPSC-derived 3D-beating clusters. (a) Calcium transient activation time map and representative traces of WT cluster recorded in
basal conditions (top), in the presence of a b-adrenergic stimulus (1mM Iso) (middle) and in coperfusion with 1 mM KN-93 (bottom) (n¼ 6). Dashed red lines indicate the
zoomed-in regions of the calcium upstroke represented below. (b) Same as (a) for CPVT clusters (n¼ 8). All traces are scaled to control value as normalized dF/F 10%.
Rainbow line indicates the isochrones of calcium impulse initiation and propagation
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inexhaustible and scalable source of differentiated patient-
specific CMs that carry the same genome as the subject they
are derived from, and in which mechanisms of the disease and
the response to drugs may be investigated.28
This study confirms the potential for human iPSC to model
inherited arrhythmogenic syndromes by establishing a
patient-specific model of CPVT in which to test therapeutic
interventions that have been successful in our murine model
of CPVT.
We performed a systematic study of the electrical properties
of iPSC-derived CMs from WT and CPVT genotypes using
the whole-cell patch clamp technique on spontaneously
beating cells at 90 days after the formation of embryoid
bodies (EBs). We did not find great heterogeneity in the
electrical parameters between the two different groups of
cells, but it was possible to highlight a pronounced within-
group variability. Furthermore, although the distinction
between atrial- and ventricular-like myocytes was not so
defined, because of the existence of cells with an intermediate
phenotype, we were able to cluster the cells into ‘working-like’
and ‘nodal-like’ CMs.6,11,24 However, the impressive hetero-
geneity in the electrical parameters is a striking feature of the
published electrophysiology data on iPSC-derived myocytes.
This could be because of the different stage of maturation of
the cells and/or to the sophisticated architecture of the
electrical structure of the heart reproduced in vitro.3
Importantly, whole-cell patch clamp and microelectrode
recordings revealed that CPVT-iPSC-derived CMs exhibited
the key features of catecholaminergic-mediated arrhythmo-
genesis. Hence, clear DADs were observed in most of the
CPVT-iPSC-CMs studied. This became even more prominent
after activation of the b-adrenergic signaling pathway and
gave rise to TA beats.
We also performed impulse-initiation optical mapping in
order to determine the electrophysiological phenotypic
defects in the context of the spontaneous beating cluster
and thus to seek the main electrical disturbance of CPVT-
induced arrhythmia. We have used this technique for the first
time to build a spatiotemporal high-resolution map for studying
the characteristics of intracellular calcium propagation in the
context of the whole CPVT cluster. We detected that calcium
transients were initiated within a delay of a few milliseconds
from multiple regions within the cluster; this resulted in a
double rise in the intracellular calcium transients, leaving the
reuptake not affected. This is in contrast with recent
observations by Novak and co-workers,13 where a prominent
diastolic calcium rise was demonstrated as an indication of
DADs. This discrepancy may be due to the diverse technical
approaches employed to optically assess calcium transients
(ratiometric versus non-ratiometric dyes). On this point, it is
worth noting that both types of dyes possess high affinity for
Ca2þ , and this can artificially prolong the calcium transient
and confound interpretation in CMs and tissues.29 On the
other hand, the fast chelation of Fluo-4 permits a better
evaluation of the calcium upstroke. A different degree of
differentiation of the beating cluster may also be a source of
variability among generated data.
Our results offer a ‘side’ view of CPVT, in which the
occurrence of calcium transient initiation at multiple foci
constitutes the arrhythmogenic substrate by underlying
altered gating kinetics of RyR2 (which may explain the double
upstroke).
Furthermore, in agreement with data previously obtained in
the RyR2R4496Cþ / CPVT mouse model,21 we demonstrate
that CaMKII inhibition prevents b-adrenergically induced
arrhythmogenesis also in patient-specific CMs. Thus, this
technique opens up the possibility of testing the response to
therapy of individual patients within the clinic. This transition
from bench to bedside is most exciting. However, the
technology needed to generate iPSC-derived CMs is still
expensive and time consuming. Nonetheless, we anticipate
the advent of novel technology that will reduce the ‘biopsy-to-
human-CMs’ time.
A few tests of substances as putative therapeutic agents on
iPSC-based CPVT models have already been reported.6,10
For example, flecainide has been recently proposed as an
antiarrhythmic drug in mice and human. However, there are
still uncertainties on the mechanism that drives its antiar-
rhythmic activity. Although some authors believe that flecai-
nide acts by inhibiting RyR2’s open state,30,31 we supported
an alternative hypothesis and demonstrated that the sodium
channel blockers of the drug is preventing DADs to activateINa
and generates triggered automaticity.32 This hypothesis
was recently supported by Sikkel et al.33 Another potential
Figure 6 Calcium transient measurements. Schematic representation of the calcium transient measurements by optical mapping fluorescence showing calcium duration
(a), calcium time to peak (b), dCa2þ /dt (percentage Ca2þ potential amplitude per s) (c) and beat per minutes (b.p.m.) (d) (*Po0.05)
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therapeutic agent for CPVT is dantrolene, a unique and very
effective therapeutic option for malignant hyperthermia: this
substance has been shown to act by stabilizing interdomain
interaction of RyR2 and decreasing loss of Ca2þ from
sarcoplasmic reticulum.6,34,35 In the present report, we
propose inhibition of CaMKII as a potential therapeutic option
for treating arrhythmias in CPVT. CaMKII is activated by
multiple pathways and, within the CM, primarily acts by
phosphorylating the main components of the calcium handling
machinery and, as such, has a clear relevance in the
pathophysiology of CPVT. Inhibition of this pathway has been
shown to be potentially advantageous compared with
b-blockers, the conventional therapy for CPVT patients;
however, the use of CaMKII inhibitors in the clinical setting
is still limited by the lack of molecules with target- and tissue-
specificity.36 The development of a human CPVT model
system and the demonstration of its ability to specifically
respond to KN-93 (no activity of the inactive analog KN-92
was detected) is instrumental to future investigations on
identifying specific targets and devising effective strategies for
the use of CaMKII inhibition in the clinical setting.
In conclusion, our work contributes to the implementation of
the available CPVT mutant models, which is mandatory for
establishing a direct relationship between specific mutations
and the observed functional effects, as well as determining
potential side effects and is fundamental for validating such
findings in the perspective of customized patient treatment.
Materials and Methods
Cell culture. Dermal fibroblasts were obtained by enzymatic digestion from 3
to 4mm skin biopsies of a patient diagnosed with CPVT after written informed
consent. Isolated fibroblasts were cultured in DMEM–low glucose/F12 (1:3)
supplemented with 10% fetal bovine serum (FBS), glutamine, 0.1 mM non-
essential amino acids and antibiotics.
Mouse embryonic fibroblasts (MEFs) were isolated from E12.5–13.5 embryos,
following a standard protocol.37 Inactivated MEFs were prepared from cells at
passage 3 by treatment with mitomycin C (10 mg/ml) for 3 h at 37 1C.
After derivation, iPSCs were initially grown on a MEF feeder layer in human
embryonic stem cell (ES) medium, that is, knockout DMEM supplemented with 20%
knockout serum replacement, 2 mM glutamax, 0.1 mM non-essential amino acids,
1% B27 supplement without vitamin A, 1% N2 supplement, 0.1 mM
b-mercaptoethanol, 50mg/ml penicillin, 50mg/ml streptomycin (all from Invitrogen,
Life Technologies, Carlsbad, CA, USA), and 20 ng/ml human basic- fibroblast
growth factor FGF (Miltenyi Biotec, Bergisch Gladbach, Germany). At passage 2–3,
iPSC lines were adapted to grow on Matrigel (human ES-qualified Matrix from BD
Biosciences, Franklin Lakes, NJ, USA) in mTESR1 medium (Stem Cell
Technologies, Vancouver, BC, Canada) as described.23
Human iPSC generation and characterization. Reprogramming was
induced by lentiviral infection, as described.38,39 In brief, lentiviral particles were
produced in human embryonic kidney 293T cells (HEK-293T) cells by independent
transfections of the four ‘pluripotency’ genes Oct4, Sox2, Nanog and Lin28
(Addgene plasmids 16 579, 16 577, 16 578 and 16 580 from Thomson Laboratory,
University of Wisconsin, Madison, WI, USA) using the calcium phosphate
method.40 Viral supernatants were collected at 30 h and used fresh for the
infection.
Low-passage fibroblasts were seeded at 8 105 cells per 100mm dish on the
day before the infection. The cells were then infected two times using an equal
amount of lentiviral particles for each gene in the presence of 4 mg/ml polybrene. Six
days later, infected fibroblasts were seeded onto MEF feeders at a low density
(5 104 cells per 100mm dish). The next day, the medium was replaced with
regular human ES cell culture medium supplemented with basic FGF.38 Valproic
acid (0.5 mM) was applied for 10 days41 to improve the efficiency of the
reprogramming process. iPSC colonies became evident around days 21–25 after
infection and were mechanically isolated based on their ES-like morphology.
Isolated clones were expanded and their pluripotency characterized through
the evaluation of ‘stemness’ marker expression and the analysis of their
developmental competence in vitro (EBs assay) and in vivo (teratoma formation
assay).3
Two clones for each subject were used for the experiments.
Immunohistological analysis and alkaline phosphatase activity.
Cells were fixed in 4% paraformaldehyde (PFA) for 20min and permeabilized with
0.2% Triton for 10min. Blocking of unspecific sites was achieved by incubation
with 10% donkey or goat serum (Sigma-Aldrich, St. Louis, MO, USA) for 1 h at
room temperature. Cells were stained with several primary antibodies, specific
for either ‘stemness’ or differentiation markers: human fibroblast surface
protein (Clone 1B10, mouse monoclonal, 1 : 100; Sigma-Aldrich), human Oct4
(mouse monoclonal, 1 : 500; Millipore, Billerica, MA, USA), human TRA1–60
(mouse monoclonal, 1 : 100; Stem Cell Technologies), human SSEA-4 (mouse
monoclonal, 1 : 100; Stem Cell Technologies), human bIII-tubulin (mouse
monoclonal, 1 : 100; Promega, Madison, WI, USA), human nestin (mouse monoclonal,
1 : 100; Millipore), human smooth muscle actin (mouse monoclonal, 1 : 20; Dako,
Glostrup, Denmark), human a-1-fetoprotein (rabbit polyclonal, 1 : 100; Dako),
human a-sarcomeric actin (rabbit polyclonal, 1 : 400; Abcam, Boston, MA, USA),
a-actinin (mouse monoclonal, 1 : 500; Sigma-Aldrich) and ryanodine receptor 2
(rabbit polyclonal, 1 : 100; Alomone labs, Jerusalem, Israel). Alexa-Fluor-488-
and -555-conjugated secondary antibodies were used for specific detection,
whereas nuclei were stained with 40,6-diamidino-2-phenylindole (DAPI). Coverslips
were mounted using Vectashield mounting medium (Vector Laboratories,
Burlingame, CA, USA). Confocal microscopy was performed with a Leica
TCS-SP2 digital scanning confocal microscope equipped with a HCX PL
APO 40/numerical aperture¼ 1.25 oil immersion objective. The pinhole
diameter was kept at Airy 1. Images were exported to Adobe Photoshop (Adobe
Systems, Mountain View, CA, USA) and created with Adobe illustrator (Adobe
Systems).
Alkaline phosphatase activity of iPSC lines was determined using the Alkaline
Phosphatase Detection kit (Millipore), after cell fixation in 4% PFA, according to the
manufacturer’s instructions. Lines were considered positive when alkaline
phosphatase activity was detected in more than 95% of iPSC lines (two clones
each condition were analyzed).
RNA extraction and RT-PCR. Total RNA was isolated using Trizol
(Invitrogen), treated with amplification grade DNAse I (Invitrogen) and reverse
transcribed to cDNA (Superscript III First-Strand Synthesis System; Invitrogen).
Real-time PCR was carried out on an ABI7900HT (Applied Biosystems,
Life Technologies, Carlsbad, CA, USA) using either the Taqman Gene
Expression Assay or the SybrGreen PCR Master Mix (Applied Biosystems), and
data were analyzed with REST (Relative Expression Software Tool) software
(http://www.gene-quantification.de/rest.html).42
Expression of cardiac-specific genes in cDNA from beating explants was
assessed with regular RT-PCR using specific primers. A complete list of the primers
used in these experiments is provided in Supplementary Table 1.
Flow cytometry analysis. Dermal fibroblasts and iPSCs were harvested
and dissociated into single cells using Trypsin and Tryple Express (Invitrogen),
respectively. Surface markers were assessed on fresh cell samples. Anti-CD13-
APC, anti-CD15-PE, anti-SSEA4-FITC and anti-TRA1-60-PE were from BD
Pharmingen (San Diego, CA, USA). Analyzes were carried out on a FACS Canto
flow cytometer (Beckton Dickinson, Franklin Lakes, NJ, USA). Data were analyzed
with DIVA software (Beckton Dickinson).
Western blot analysis. Whole-cell lysates were obtained from control (WT)
and CPVT iPSC-derived beating explants and analyses preformed using 25 mg of
proteins following standard procedures. Proteins from human fetal heart (FH) were
used as positive control. Monoclonal anti-RyR2 (1 : 1000; Thermo Fisher,
Waltham, MA, USA) and polyclonal anti-b Actin (1 : 2000; Santa Cruz
Biotechnologies, Dallas, TX, USA) antibodies were used for detection.
Quantification of RyR2 expression levels was determined using Fiji software (Open
Source image processing package available at the website: http://fiji.sc/Fiji).36
Genomic sequencing and karyotyping. Genomic DNA was isolated
from control- and CPVT-derived iPSC lines (two clones each) by DNeasy Blood
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and tissue kit (Qiagen, Venlo, Limburg, Netherlands). Purified DNA was amplified
with Bid Dye Terminator v.1.1 Sequencing RR-100 (Applied Biosystem) with
specific primers and analyzed with a 3130xl Genetic Analyzer (Applied Biosystem
and Hitachi, Chiyoda, Tokyo, Japan). Chromosomal G-banding analysis was
performed by the University of Milan-Bicocca Cytogenetics Laboratory (Milan,
Italy), using standard procedures.
Spontaneous differentiation and cardiac induction. Control and
CPVT iPSCs were differentiated by aggregation into EBs: iPSC colonies were
detached using 1mg/ml dispase (Roche, Basel, Switzerland) and plated onto
ultra-low-attachment plates (Corning, Incorporated, Corning, NY, USA) in EB
differentiation medium, that is, DMEMF12 medium supplemented with 20% FBS,
0.1 mM non-essential amino acids, glutamine and antibiotics. After 7 days, EBs
were plated onto gelatin-coated dishes for further differentiation.
For cardiac lineage induction, ascorbic acid (50 mg/ml) was added to the medium.
Spontaneously contracting areas, which appeared 12–30 days after EB plating,
were manually microdissected and plated onto fibronectin-coated plates for further
differentiation for an additional 45–90 days. Explants were maintained in EB
differentiation medium supplemented with FBS at only 2%. For single-cell analyses
(electrophysiological and immunofluorescence analyses), cells were dissociated as
described previously9 and plated onto fibronectin-coated plastic or glass 2-well
chamber slides (Nunc, Nalge Nunc International, Penfield, NY, USA).
Teratoma assay. iPSC lines were harvested by dispase treatment,
resuspended in X-VIVO medium (Lonza, Basel, Switzerland), and injected
subcutaneously into immunodeficient mice (NOD-SCID or Rag / (mice
homozygous for the scid mutation (severe-combined immunodeficiency) are
severely deficient in functional B and T lymphocytes)). Teratomas formed
9–15 weeks after injection were collected and processed according to
standard procedures for paraffin embedding and hematoxylin–eosin and
immunohistochemical staining.
Recording of APs. Cells were seeded on poly-lysine-like-covered slides
(Lab-Tek II, Nunc) and kept in differentiation medium for about 2 months.
APs from spontaneously contracting iPSC-CMs were recorded using the patch-
clamp technique in the whole-cell configuration with a MultiClamp 700B
amplifier (Axon Instruments, Sunnyvale, CA, USA). The experiments were
performed at 37 1C under continuous perfusion of extracellular solution
containing (in mM): 140 NaCl, 4 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES and 5
glucose (pH adjusted to 7.40 with NaOH). Patch-clamp pipettes, formed from
borosilicate glass with a P-97 horizontal puller (Sutter Instruments, Novato,
CA, USA), and had a resistance of 2–3 MO when filled with an intracellular
solution containing (in mM): 20 KCl, 120K-aspartate, 1 MgCl2, 4 Na2-ATP, 0.1
GTP, 10 glucose and 10 HEPES (pH adjusted to 7.20 with KOH). Some
experiments were carried out with intracellular electrophysiology recordings. In
this case, spontaneously beating EBs were impaled using sharp glass
microelectrodes with resistances Z10 MO. Electrode capacitance was nulled
and the recordings were made using the previously described MultiClamp
700B amplifier in gap-free mode. Solutions containing 1 mM Iso, 1 mM KN-93 or
KN-92 were prepared fresh before the experiments and applied using a
gravitational flow system for 2–3 min before data collection. All signals were
acquired at 10 KHz, digitized (Digidata 1332A; Axon Instruments) and
analysed with pCLAMP 9.2 software (Axon Instruments).
Definition of delayed APs and TA. We defined DADs as low-amplitude
depolarizations following completion of repolarization, and have an amplitude
Z5% of the preceding AP. TA was defined as an AP developing from a DAD
rather than from an external stimulus.
Fast optical mapping of intracellular calcium transient. Intracellular
calcium transient characteristics were measured as described previously.43
Briefly, ectopic clusters from CPVT and WT were excised and recultured onto
22mm glass coverslip. After 48–96 h, the coverslips were immersed in a 1ml
solution containing culture medium plus 2.5mmol/l of Fluo-4 AM (Invitrogen, Life
Technologies) and incubated for 20min at 37 1C. Afterwards, the coverslips were
mounted onto a custom-made microscope chamber and perfused with Tyrode
solution at 37 1C containing (in mM): 140 NaCl, 4 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES
and 5 glucose (pH adjusted to 7.40 with NaOH). Optical recording of intracellular
calcium transient were assessed using a CMOS fast resolution camera (Ultima L;
Scimedia, Costa Mesa, CA, USA) mounted on an inverted microscope (Nikon Ti/U
from Nikon Instruments, Chiyoda, Tokyo, Japan) and acquired for 8 s at 0.5 KHz at
 10 magnification. To reduce the light exposure, the synchronization of the light
shutter and the acquisition was achieved using Digidata 1440A (Molecular Devices,
Sunnyvale, CA, USA; Crisel IT) by programming a dedicate protocol of acquisition.
Recordings were analysed using BV-Analysis v.1208 (Scimedia).
Statistical analysis. Data are represented as mean±MSE (or mean±S.D.
where indicated). The significance of differences between two groups was
evaluated with unpaired Student’s t-test. Po0.05 was considered statistically
significant. Single asterisk indicates Po0.05, whereas double asterisks indicate
Po0.01.
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